Catherine Kingery, NP
Women's Health · Knoxville, TNNPI 1851512818
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,784 of the $6,554 with a category attached, or 88.2%. 38 manufacturers reported payments, led by Axonics, Inc. at 24.1% of the total. Reporting peaked in 2021 at $2,233 and has fallen 54.0% since, to $1,027 in 2025. Among women's health clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 308 payments — averaging $21.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Axonics, Inc.$2K
- AbbVie$650
- Exeltis, USA Inc.$515
- Lundbeck LLC$491
- Mayne Pharma Commercial LLC$356
- Myovant Sciences Inc.$284
- plus $3K from 32 others
What the payments were for
- Travel & lodging$69411%
- Food & beverage$5,78488%
- Education$761%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Axonics, Inc. | 30 | $1,579 |
| AbbVie | 43 | $650 |
| Exeltis, USA Inc. | 33 | $515 |
| Lundbeck LLC | 23 | $491 |
| Mayne Pharma Commercial LLC | 25 | $356 |
| Myovant Sciences Inc. | 19 | $284 |
| Daiichi Sankyo Inc. | 15 | $257 |
| Astellas Pharma US Inc | 8 | $238 |
| Sumitomo Pharma America, Inc. | 11 | $236 |
| Shield Therapeutics Inc | 11 | $180 |
| Boston Scientific | 8 | $161 |
| Novo Nordisk | 9 | $158 |
| Aspira Women's Health Inc | 3 | $154 |
| Lilly USA, LLC | 11 | $145 |
| Therapeuticsmd, Inc. | 8 | $121 |
| Dysis Medical, Inc. | 1 | $108 |
| Organon | 5 | $97 |
| Kowa Pharmaceuticals America, Inc. | 6 | $92 |
| Pfizer | 5 | $81 |
| Scynexis, Inc. | 4 | $69 |
| Agile Therapeutics, Inc. | 4 | $68 |
| Idorsia Pharmaceuticals US Inc | 3 | $51 |
| Sage Therapeutics, LLC | 3 | $48 |
| Millicent US Inc | 2 | $47 |
| Laborie Medical Technologies Corp. | 1 | $45 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $45 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $43 |
| Coloplast | 2 | $35 |
| Hologic Sales And Service, LLC | 2 | $32 |
| Baxter Healthcare | 1 | $27 |
| Roche Diagnostics Corporation | 1 | $23 |
| Merz North America, Inc. | 1 | $23 |
| Lupin Inc. | 1 | $17 |
| Bayer | 1 | $17 |
| IBSA Pharma Inc. | 1 | $16 |
| Supernus Pharmaceuticals, Inc. | 1 | $15 |
| Merck | 1 | $15 |
| Avion Pharmaceuticals | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,554 in reported general payments places this provider in the 95th percentile of 202 women's health providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 13 | $10,071 |
| Estradiol | 93 | $3,983 |
| Estradiol (Once Weekly)Estradiol | 17 | $1,294 |
| Clobetasol Propionate | 12 | $426 |
| Fluconazole | 19 | $148 |
| Levothyroxine Sodium | 21 | $80 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $238 | $10,07113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 202 women's health providers in Tennessee.
Other women's health in Knoxville
- Anya ZerillaKnoxville$8K
- Brynn WhitworthKnoxville$2K
- Donna DossettKnoxville$2K
- Elizabeth ThurmanKnoxville$1K
- Haley WoodFranklin$92K
- Dana DemossNashville$76K
- Royanne MooreNashville$29K
- Laurie TompkinsBrentwood$27K
- Lana HirschNashville$24K
- Yoshie DarnallNashville$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.